Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of TTHX1114(NM141) Ophthalmic Solution In Healthy Adult Volunteers

NCT05769920 is registered in ClinicalTrials.gov with Trefoil Therapeutics, Inc. as lead sponsor.

NCT NCT05769920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05769920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of TTHX1114(NM141) Ophthalmic Solution In Healthy Adult Volunteers
Lead sponsor
Trefoil Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 6, 2022
Completion date
April 12, 2023
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

corneal epithelial degeneration